Northern California Retina Vitreous Associates Medical Group | Mountain View, CA

Research site

(Unclaimed)

Location

2495 Hospital Drive Suite 545, Mountain View, California, United States of America

Site insights

Top conditions

Top treatments

Abicipar Pegol

AR-14034

ANX007

THR-149

SF0166

Sunitinib Malate

EYP-1901

Aflibercept

GB-102

steroid

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 20 total trials

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Active, not recruiting

Wet Age Related Macular Degeneration

wAMD

Drug: Aflibercept (2.0 mg)

Drug: EYP-1901

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy (SIENNA)

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atroph...

Enrolling

Age-related Macular Degeneration (AMD)

Geographic Atrophy (GA)

Drug: Placebo

Drug: Pozelimab

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA) (ARCHER II)

The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with GA secondary to...

Active, not recruiting

Geographic Atrophy

Drug: Vonaprument

Other: Sham Administration

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD (ATMOSPHERE)

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling

Choroidal Neovascularization

Wet Age-related Macular Degeneration

Genetic: ABBV-RGX-314

Biological: Ranibizumab (LUCENTIS®)

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) (ALTITUDE®)

ABBV-RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of Diabetic Retinopathy (DR) with and without...

Active, not recruiting

Diabetic Retinopathy (DR)

Center-Involved Diabetic Macular Edema (CI-DME)

Genetic: ABBV-RGX-314 Dose 4

Biological: Aflibercept

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)

This interventional study is being conducted with an investigational gene therapy treatment called ABBV-RGX-314 (also known as RGX-314) and is being...

Enrolling

Neovascular Age-Related Macular Degeneration (nAMD)

Genetic: ABBV-RGX-314 Dose 3

Genetic: ABBV-RGX-314 Dose 2

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (NOVA-1)

The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in...

Enrolling

Neovascular Age-related Macular Degeneration (nAMD)

Drug: AR-14034 SR implant lower dose

Drug: Sham procedure